Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Page 1
Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative.
Dunton CJ, Hutchcraft ML, Bullock RG, Northrop LE, Ueland FR. Dunton CJ, et al. Among authors: bullock rg. Diagnostics (Basel). 2021 Aug 10;11(8):1440. doi: 10.3390/diagnostics11081440. Diagnostics (Basel). 2021. PMID: 34441373 Free PMC article.
This is particularly important for premenopausal women and early-stage cancers, which have a much better long-term survival than late-stage malignancies. Using OVA1 in the setting of a normal serum CA125 can help identify at-risk ovarian tumors for referral to a gynecologi …
This is particularly important for premenopausal women and early-stage cancers, which have a much better long-term survival than late …
A phase II trial of tideglusib in Alzheimer's disease.
Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T, del Ser T; ARGO investigators. Lovestone S, et al. J Alzheimers Dis. 2015;45(1):75-88. doi: 10.3233/JAD-141959. J Alzheimers Dis. 2015. PMID: 25537011 Clinical Trial.
Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, 3.5% placebo) were the most frequent adverse events. CONCLUSIONS: Short term (26 weeks) tideglusib was acceptably safe but produced n …
Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, …
Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study.
Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset PJ, Cesari M; ICTUS/DSA Group. Canevelli M, et al. Phytomedicine. 2014 May 15;21(6):888-92. doi: 10.1016/j.phymed.2014.01.003. Epub 2014 Feb 16. Phytomedicine. 2014. PMID: 24548724 Free article.
No significant modifications of the two adopted outcome measures were observed at the mid-term 6-month evaluation. The modifications over time of the ADL score did not show statistically significant differences between the two groups of interest. ...
No significant modifications of the two adopted outcome measures were observed at the mid-term 6-month evaluation. The modifications …
A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer's disease in Europe : predictors of discontinuation and switch in the ICTUS study.
Gardette V, Lapeyre-Mestre M, Piau A, Gallini A, Cantet C, Montastruc JL, Vellas B, Andrieu S; ICTUS Group. Gardette V, et al. CNS Drugs. 2014 Feb;28(2):157-70. doi: 10.1007/s40263-013-0133-3. CNS Drugs. 2014. PMID: 24408842
Predictors of non-persistency of antidementia drugs have been poorly investigated, mostly during short-term periods and using administrative data. OBJECTIVE: The aim of this study was to investigate the incidence and predictors of ChEI switch and discontinuation among subj …
Predictors of non-persistency of antidementia drugs have been poorly investigated, mostly during short-term periods and using adminis …
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Davies C, et al. Lancet. 2013 Mar 9;381(9869):805-16. doi: 10.1016/S0140-6736(12)61963-1. Lancet. 2013. PMID: 23219286 Free PMC article. Clinical Trial.
We report effects on breast cancer outcomes among the 6846 women with ER-positive disease, and side-effects among all women (with positive, negative, or unknown ER status). Long-term follow-up still continues. This study is registered, number ISRCTN19652633. ...
We report effects on breast cancer outcomes among the 6846 women with ER-positive disease, and side-effects among all women (with positive, …
Cholinesterase inhibition: is there evidence for disease-modifying effects?
Shanks M, Kivipelto M, Bullock R, Lane R. Shanks M, et al. Among authors: bullock r. Curr Med Res Opin. 2009 Oct;25(10):2439-46. doi: 10.1185/03007990903209332. Curr Med Res Opin. 2009. PMID: 19678754 Review.
The detection of putative disease-modifying effects may be most easily implemented in certain patient subpopulations, and genotyping studies suggest a particular role for BuChE. CONCLUSION: Long-term inhibition of BuChE might be especially important when exploring any dise …
The detection of putative disease-modifying effects may be most easily implemented in certain patient subpopulations, and genotyping studies …
Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
Hatoum HT, Thomas SK, Lin SJ, Lane R, Bullock R. Hatoum HT, et al. Among authors: bullock r. J Med Econ. 2009 Jun;12(2):98-103. doi: 10.3111/13696990903004039. J Med Econ. 2009. PMID: 19492974 Free article.
Over 2 years, risk of NHP increased by 3% for each 1-point deterioration in ADL score independent of cognition. CONCLUSION: Data analyses from this long-term clinical trial established that daily functioning is an important predictor of time to NHP. ...
Over 2 years, risk of NHP increased by 3% for each 1-point deterioration in ADL score independent of cognition. CONCLUSION: Data analyses fr …
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Holmes C, et al. Among authors: bullock r. Lancet. 2008 Jul 19;372(9634):216-23. doi: 10.1016/S0140-6736(08)61075-2. Lancet. 2008. PMID: 18640458 Free article.
Our aim was to assess the relation between Abeta(42) immune response, degree of plaque removal, and long-term clinical outcomes. METHODS: In June, 2003, consent for long-term clinical follow-up, post-mortem neuropathological examination, or both, was sought from 80 …
Our aim was to assess the relation between Abeta(42) immune response, degree of plaque removal, and long-term clinical outcomes. METH …
Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal ventilation in improving survival.
Eagle M, Bourke J, Bullock R, Gibson M, Mehta J, Giddings D, Straub V, Bushby K. Eagle M, et al. Among authors: bullock r. Neuromuscul Disord. 2007 Jun;17(6):470-5. doi: 10.1016/j.nmd.2007.03.002. Epub 2007 May 8. Neuromuscul Disord. 2007. PMID: 17490881
OBJECTIVES: To determine the long term survival in patients with Duchenne muscular dystrophy (DMD) following spinal surgery and nocturnal ventilation. ...
OBJECTIVES: To determine the long term survival in patients with Duchenne muscular dystrophy (DMD) following spinal surgery and noctu …
25 results